

Supplementary Fig. S1. (**A**) Western blot analysis for Wnt1 in T47D, ZR-75, MDA-MB-468, SKBR3 and MDA-MB-435 cells. (**B**)T47D, ZR-75, MDA-MB-468, SKBR3 and MDA-MB-435 breast cancer cell lines were fractionated into nuclear (N) and cytoplasmic (C) fractions, and status of β-catenin was analyzed by Western blotting. PARP and paxillin were used as a markers for the nuclear and cytoplasmic fractions respectively. Numbers underneath the panels refer to the relative ratios of β-catenin in the cytoplasmic and nuclear fractions.

MTA1s positive	Wnt1 positive	Wnt1 negative	% of samples with double (MTA1s + Wnt1) positive
18	14	4	77.77
MTA1s negative	**Wnt1 positive**	**Wnt1 negative**	**% of samples with double (MTA1s + Wnt1) negative**
42	11	31	73.8

Supplementary Fig. S2. Summary of the expression of Wnt1 and MTA1s in human breast cancer specimens.



Supplementary Fig. S3. (**A**) Western analysis of β-catenin expression in ZR-75/pcDNA and ZR-75/MTA1s stable clones. (**B**) ZR-75/pcDNA and ZR-75/MTA1s cells were fractionated into nuclear (N) and cytoplasmic (C) fractions and status of β-catenin was analyzed by Western blotting. PARP and paxillin were used as markers for the nuclear and cytoplasmic fractions respectively. Numbers underneath the panels refer to the relative ratios of β-catenin in the cytoplasmic and nuclear fractions.